657 related articles for article (PubMed ID: 17919546)
1. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.
Pastores GM; Elstein D; Hrebícek M; Zimran A
Clin Ther; 2007 Aug; 29(8):1645-54. PubMed ID: 17919546
[TBL] [Abstract][Full Text] [Related]
2. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
Pastores GM; Barnett NL; Kolodny EH
Clin Ther; 2005 Aug; 27(8):1215-27. PubMed ID: 16199246
[TBL] [Abstract][Full Text] [Related]
3. Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme.
Hollak CE; Hughes D; van Schaik IN; Schwierin B; Bembi B
Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):770-7. PubMed ID: 19507165
[TBL] [Abstract][Full Text] [Related]
4. Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher's disease.
Giraldo P; Latre P; Alfonso P; Acedo A; Alonso D; Barez A; Corrales A; Franco R; Roldan V; Serrano S; Pocovi M
Haematologica; 2006 May; 91(5):703-6. PubMed ID: 16627252
[TBL] [Abstract][Full Text] [Related]
5. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations.
Piran S; Roberts A; Patterson MA; Amato D
Blood Cells Mol Dis; 2009; 43(3):289-93. PubMed ID: 19793665
[TBL] [Abstract][Full Text] [Related]
6. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.
Lange U; Teichmann J; Müller-Ladner U; Strunk J
Rheumatology (Oxford); 2005 Dec; 44(12):1546-8. PubMed ID: 16263785
[TBL] [Abstract][Full Text] [Related]
7. Velaglucerase alfa for the management of type 1 Gaucher disease.
Morris JL
Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
[TBL] [Abstract][Full Text] [Related]
8. Osteopenia in children who have undergone posterior fossa or craniospinal irradiation for brain tumors.
Krishnamoorthy P; Freeman C; Bernstein ML; Lawrence S; Rodd C
Arch Pediatr Adolesc Med; 2004 May; 158(5):491-6. PubMed ID: 15123484
[TBL] [Abstract][Full Text] [Related]
9. Reduced bone mineral density at diagnosis and bone mineral recovery during treatment in children with Graves' disease.
Lucidarme N; Ruiz JC; Czernichow P; Léger J
J Pediatr; 2000 Jul; 137(1):56-62. PubMed ID: 10891822
[TBL] [Abstract][Full Text] [Related]
10. Factors influencing changes in bone mineral density in patients with anorexia nervosa-related osteoporosis: the effect of hormone replacement therapy.
Legroux-Gerot I; Vignau J; Collier F; Cortet B
Calcif Tissue Int; 2008 Nov; 83(5):315-23. PubMed ID: 18836675
[TBL] [Abstract][Full Text] [Related]
11. Four years follow-up of bone mineral density change in premenopausal women with systemic lupus erythematosus.
Uaratanawong S; Deesomchok U; Hiransuttikul N; Uaratanawong S
J Med Assoc Thai; 2004 Nov; 87(11):1374-9. PubMed ID: 15825716
[TBL] [Abstract][Full Text] [Related]
12. The effect of growth hormone treatment on bone mineral density in prepubertal girls with Turner syndrome: a multicentre prospective clinical trial.
Aycan Z; Cetinkaya E; Darendeliler F; Vidinlisan S; Bas F; Bideci A; Demirel F; Darcan S; Buyukgebiz A; Yildiz M; Berberoglu M; Bundak R
Clin Endocrinol (Oxf); 2008 May; 68(5):769-72. PubMed ID: 17980015
[TBL] [Abstract][Full Text] [Related]
13. Effects of vibration therapy on bone mineral density in postmenopausal women with osteoporosis.
Ruan XY; Jin FY; Liu YL; Peng ZL; Sun YG
Chin Med J (Engl); 2008 Jul; 121(13):1155-8. PubMed ID: 18710630
[TBL] [Abstract][Full Text] [Related]
14. Corticosteroid-induced osteoporosis: does it occur in patients with Crohn's disease?
de Jong DJ; Corstens FH; Mannaerts L; van Rossum LG; Naber AH
Am J Gastroenterol; 2002 Aug; 97(8):2011-5. PubMed ID: 12190169
[TBL] [Abstract][Full Text] [Related]
15. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
[TBL] [Abstract][Full Text] [Related]
16. Bone mineral density in postmenarchal adolescent girls in the United States: associated biopsychosocial variables and bone turnover markers.
Harel Z; Gold M; Cromer B; Bruner A; Stager M; Bachrach L; Wolter K; Reid C; Hertweck P; Nelson A; Nelson D; Coupey S; Johnson C; Burkman R; Bone H
J Adolesc Health; 2007 Jan; 40(1):44-53. PubMed ID: 17185205
[TBL] [Abstract][Full Text] [Related]
17. Frequency of osteopenia in adolescents with early-onset juvenile idiopathic arthritis: a long-term outcome study of one hundred five patients.
Lien G; Flatø B; Haugen M; Vinje O; Sørskaar D; Dale K; Johnston V; Egeland T; Førre Ø
Arthritis Rheum; 2003 Aug; 48(8):2214-23. PubMed ID: 12905475
[TBL] [Abstract][Full Text] [Related]
18. Disease activity and disability but probably not glucocorticoid treatment predicts loss in bone mineral density in women with early rheumatoid arthritis.
Book C; Karlsson M; Akesson K; Jacobsson L
Scand J Rheumatol; 2008; 37(4):248-54. PubMed ID: 18612924
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia.
Gilfillan CP; Strauss BJ; Rodda CP; Bowden DK; Kean AM; Obaid M; Crawford BA
Calcif Tissue Int; 2006 Sep; 79(3):138-44. PubMed ID: 16969592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
